Reimbursement of pharmaceuticals: Reference pricing versus health technology assessment

European Journal of Health Economics

Volumn 12, Issue 3, 2011, Pages 263-271

  Drummond, Michael ^a   Jönsson, Bengt ^b   Rutten, Frans ^c   Stargardt, Tom ^d  

^a UNIVERSITY OF YORK   (United Kingdom)

^b STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Cost effectiveness analysis; Health policy; Pharmaceuticals; Reimbursement

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; ARIPIPRAZOLE; ATORVASTATIN; ATYPICAL ANTIPSYCHOTIC AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; HYPOCHOLESTEROLEMIC AGENT; INFLIXIMAB; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN LISPRO; METHOTREXATE; OLANZAPINE; QUETIAPINE; RISPERIDONE; ROSUVASTATIN;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DIABETES MELLITUS; DRUG COST; DRUG INDICATION; DRUG INDUSTRY; GERMANY; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH TECHNOLOGY ASSESSMENT; HUMAN; HYPERLIPIDEMIA; NETHERLANDS; PRIORITY JOURNAL; REIMBURSEMENT; RHEUMATOID ARTHRITIS; SCHIZOPHRENIA; SWEDEN; UNITED KINGDOM;

ANTICHOLESTEREMIC AGENTS; ANTIPSYCHOTIC AGENTS; ANTIRHEUMATIC AGENTS; COST CONTROL; COSTS AND COST ANALYSIS; EUROPE; HEALTH POLICY; HUMANS; INSULIN; INSURANCE, HEALTH, REIMBURSEMENT; PRESCRIPTION DRUGS; REFERENCE VALUES; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 79958039205     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-010-0274-y     Document Type: Article

References (25)

1. Barbieri, M., Hawkins, N., Sculpher, M.: Who does the numbers? The role of third-party technology assessment to inform health systems' decision-making about the funding of health technologies. Value Health. (2008) Epub ahead of print
2. Brouwer, W., Rutten, F.: The Netherlands. In: Rapoport, J., Jacobs, P., Jonsson, E. (eds.) Cost Containment and Efficiency in National Health Systems: A Global Comparison. Wiley, Weinheim (2009)
3. R Busse J Schreyogg K-D Henke 2005 Pharmaceutical regulation in Germany: Improving efficiency and controlling expenditures Int. J. Health Plan. Manag. 20 329 349 10.1002/hpm.818 (Pubitemid 41781487)
4. J Cairns 2006 Providing guidance to the NHS: The Scottish medicines consortium and the National Institute for clinical excellence compared Health Policy 76 134 143 15982779 10.1016/j.healthpol.2005.05.006 (Pubitemid 43330597)
5. K Claxton 2007 OFT, VBP; QED? Health Econ. 16 545 558 17535009 10.1002/hec.1249 (Pubitemid 46915878)
6. Drummond, M.F., Rutten, F.F.H.: New Methodological Guidelines in England and Germany: Are We Any Closer to Agreeing International Standards. Office for Health Economics, London (2008)
7. Drummond, M.F., Sorenson, C.: Use of pharmacoeconomics in drug reimbursement in Australia, Canada and the United Kingdom: what can we learn from international experience? In: Arnold, R.G. (ed.) Pharmacoeconomics From Theory to Practice. CRC Press, Boca Raton USA (2009)
8. Engström, A., Jacob, J., Lundin, D.: Sharp drop in prices after introduction of generic substitution. LFN (now TLV), http://www.tlv.se (2006). Accessed 13 Mar 2009
9. IQWiG: Rapid-Acting Insulin Analogues for the Treatment of Diabetes Mellitus Type 2. Institute for Quality and Efficiency in Health Care (IQWiG), Koeln (2006)
10. IQWiG: Nutzenbewertung der Statine unter Besonderer Beruecksichtigung von Atorvastatin. Institute for Quality and Efficiency in Health Care (IQWiG), Koeln (2005)
11. IQWiG: General Methods 3.0. Institute for Quality and Efficiency in Health Care (IQWiG), Koeln (2008)
12. Jönsson, B.: Reference pricing: central economic and policy issues. In: López-Casasnovas, G., Jönsson, B. (eds.) Reference Pricing and Pharmaceutical Policy, pp. 80-85. Springer, Barcelona (2001)
13. Jönsson, B., Kobelt, G., Smolen, J.: The burden of rheumatoid arthritis and access to treatment: Uptake of new therapies. Eur. J. Health Econ. (Suppl. 2), S61-S86 (2008)
14. López-Casasnovas, G., Jönsson, B. (eds.): Reference Pricing and Pharmaceutical Policy, pp. 80-85. Springer, Barcelona (2001)
15. Mason, A., Drummond, M.F., Towse, A.: Economic Post-Launch Studies: Matching the Desirable With the Feasible. Office of Health Economics, London (2006)
16. National Institute for Health and Clinical Excellence: Statins for the Prevention of Cardiovascular Events. Technology Appraisal 94. NICE, London (2006)
17. National Institute for Health and Clinical Excellence: Guidance on the Use of Long-Acting Insulin Analogues for the Treatment of Diabetes-Insulin Glargine. Technology Appraisal 53. NICE, London (2002)
18. National Institute for Health and Clinical Excellence: Schizophrenia-Atypical Antipsychotics. Technology Appraisal 43. NICE, London (2002)
19. National Institute for Health and Clinical Excellence: Adalimumab, Etanercept and Infiximab for the Treatment of Rheumatoid Arthritis. Technology Appraisal 130. NICE, London (2007)
20. National Institute for Health and Clinical Excellence: Guide to the Methods of Technology Appraisal. NICE, London (2007)
21. National Institute for Health and Clinical Excellence: Multiple Myeloma-Bortezomib. Technology Appraisal 129. NICE, London (2007)
22. MJ Sculpher MF Drummond 2006 Analysis sans frontiers: Can we ever make economic evaluations generalisable across jurisdictions? PharmacoEconomics. 24 1087 1099 17067194 10.2165/00019053-200624110-00006 (Pubitemid 44683366)
23. T Stargardt J Schreyögg R Busse 2005 Arzneimittelfestbetraege: gruppenbildung, preisberechnung mittels regressionsverfahren und wirkungen Das Gesundheitswesen. 67 468 477 16103970 10.1055/s-2005-858485 1:STN:280: DC%2BD2Mvpt1ynsw%3D%3D (Pubitemid 41243047)
24. Taylor, R.S., Drummond, M.F., Salkeld, G., Sullivan, S.D.: Chapter 5: Development of fourth hurdle policies around the world. In: Freemantle, N., Hill, S. (eds.) Evaluating pharmaceuticals for health policy and reimbursement. BMJ Books, London (2004)
25. TLV.: Review of drugs for lipid disorders. http://www.tlv.se (2009). Accessed 22 Feb 2009